Standard Biotools Inc — Current Report (Form 8-K)

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (date of earliest event reported): June 17, 2026

Standard BioTools Inc.

(Exact name of registrant as specified in its charter)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Standard BioTools Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”) on June 17, 2026. The Company’s stockholders voted to approve the Company’s 2026 Equity Incentive Plan (the “2026 Plan”) and an amendment to the Company’s Amended and Restated 2017 Employee Stock Purchase Plan (the “ESPP”), increasing the number of shares of common stock reserved for issuance thereunder by 1,200,000 shares.

The 2026 Plan and the ESPP are described in further detail in the Company’s definitive proxy statement on Schedule 14A for the Annual Meeting filed with the Securities and Exchange Commission on April 27, 2026 (the “Proxy Statement”), which descriptions are incorporated herein by reference. The complete text of the 2026 Plan and the ESPP are set forth in Exhibits 10.1 and 10.2, respectively, to this Current Report on Form 8-K and are incorporated herein by reference.

Item 5.07. Submission of Matters to a Vote of Security Holders.

On April 24, 2026 (the “Record Date”), the Company had 390,368,119 shares of common stock issued and outstanding. A total of 335,900,644 votes, or approximately 86.04% of the total voting power of the shares of the Company’s capital stock issued and outstanding and entitled to vote at the Annual Meeting were represented in person or by proxy at the Annual Meeting. The following proposals are described in detail in the Proxy Statement. The final voting results for each of the matters submitted to a stockholder vote at the Annual Meeting are set forth below:

1. Election of Class I Directors. The following nominees were elected to serve as Class I directors, to hold office until the Company’s 2029 Annual Meeting of Stockholders or until their respective successors have been duly elected and qualified or their earlier resignation or removal:

2. Advisory Vote on Approval of Executive Compensation. The proposal to approve, on an advisory basis, the compensation of the Company’s named executive officers for the year ended December 31, 2025 was approved by the following votes:

3. Ratification of Appointment of Independent Registered Public Accounting Firm. The proposal to ratify the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2026 was approved by the following vote:

4. Approval of the 2026 Equity Incentive Plan. The proposal to approve the 2026 Plan was approved by the following votes:

5. Approval of the Amendment to the Amended and Restated 2017 Employee Stock Purchase Plan. The proposal to approve the amendment to the ESPP to increase the shares of common stock reserved thereunder by 1,200,000 shares was approved by the following votes:

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

________________________

+ Management compensation plan or arrangement.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.